Evidence map›Paper›PMID 37292153›Full record

ArticleFrontiers in pharmacology2023

Integrated high-throughput analysis identifies super enhancers in metastatic castration-resistant prostate cancer.

Jie Zeng, Jiahong Chen, Maozhang Li, Chuanfan Zhong, Zezhen Liu, Yan Wang, Yuejiao Li, Funeng Jiang, Shumin Fang, Weide Zhong

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Neurobiology of stress · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Jie ZengDepartment of Urology, The Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.
Jiahong ChenDepartment of Urology, Huizhou Municipal Central Hospital, Huizhou, Guangdong, China.
Maozhang LiDepartment of Urology, Huizhou Municipal Central Hospital, Huizhou, Guangdong, China.
Chuanfan ZhongZhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Zezhen LiuDepartment of Urology, Minimally Invasive Surgery Center, The First Affiliated Hospital of Guangzhou Medical University, and Guangdong Key Laboratory of Urology, Guangzhou, Guangdong, China.
Yan WangDepartment of Urology, The Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.
Yuejiao LiDepartment of Urology, The Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.
Funeng JiangDepartment of Urology, The Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.
Shumin FangDepartment of Urology, Huizhou Municipal Central Hospital, Huizhou, Guangdong, China.
Weide ZhongDepartment of Urology, The Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.
South China University of Technology · CNHuizhou Central People's Hospital · CNFirst Affiliated Hospital of Guangzhou Medical University · CNZhujiang Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CUT&TagmCRPCprostate cancersuper enhancertranscription factor

Identifiers

PMID37292153
PMCPMC10244677
OpenAlexW4378072344

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.